KING OF PRUSSIA, PA –March 30, 2026 – SEEDTherapeutics, Inc. (“SEED”), a clinical-stagebiotechnology company specializing in molecular glue degraders, today announced that it willhave a poster presentation at the 2026 Annual Meeting of the AmericanAssociation for Cancer Research ("AACR"), taking place on April 17 through 22, 2026in San Diego, California.

PresentationDetails:

·      Title: RBM39 Degrader AnticancerActivity Against Neuroblastoma; MYC and CDKN2A/B as PotentialResponse Biomarkers

·      Presenter /Authors: James Finn,Imad Salhab, Haihong Jin, Fei Liu, Dong Liu, Yunkai Zhang, Xing Liu, JamesTonra, Lan Huang, Dan Lu

·      PresentationTime: April 21, 2026, 2PM to 5PM PT

·      Location: Poster Section 15 at San Diego ConventionCenter

·      Session Category: Experimental and Molecular Therapeutics

·      SessionTitle: Proximity-InducedDrug Discovery 2

·      Poster BoardNumber: 12

·      PosterNumber: 5785

About SEED Therapeutics

SEED Therapeutics is aclinical-stage biotechnology company pioneering rationally designed molecularglue degraders to treat diseases driven by undruggable proteins. Itsproprietary RITE3™ platform enables targeted protein degradation withsmall-molecule precision.

SEED Therapeutics wasco-founded by fourscientific leaders:

·      NobelLaureate Prof. Avram Hershko, discoverer of the ubiquitin-proteasome system

·      Dr. LanHuang, solved the first E3 Ligase structure and a serial biotech entrepreneur

·      Prof. NingZheng (University of Washington, HHMI Investigator), pioneer ofRING-finger E3 Ligase structures and coined the term “molecular glue”

·      Prof.Michele Pagano (NYU Grossman School of Medicine, HHMI Investigator), apreeminent expert on E3 ligase biology

Eli Lilly and Co. and Eisai Co., Ltd., are cornerstoneinvestors and research collaborators, supporting SEED’s mission to unlockundruggable disease targets. The company’s pipeline includes six molecular glueprograms across oncology, neurodegeneration, immunology, and virology.

Media & Investor Contact
IR@seedtherapeutics.com
PR@seedtherapeutics.com
www.seedtherapeutics.com

‍